Walking Fish Therapeutics

Five Prime Therapeutics, Inc.

Srinivas Kothakota

Lewis T Williams

Thomas Brennan

Hangil Park

Jeffrey T Finer

Kevin Hestir

Shannon Marshall

Kalyani Penta

Yan Wang

Kathleen Boyle

Mark Selby

The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell ('CAR-B cell'), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Modified B cells and methods of use thereof

The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell ('CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor'), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.

Compositions for treating arthritis comprising HG1023575 polypeptide

Growing community of inventors

Pacifica, CA, United States of America

Srinivas Kothakota